Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Propranolol · Inderal, Inderal Xl

Small molecule · Antagonist of beta-adrenergic receptor · developed by Wyeth Pharms

Approved FDA, Nov 1967
1 Registered trials

What is Propranolol?

Propranolol is a nonselective beta-adrenergic receptor blocker that competitively antagonizes beta-adrenergic receptors, reducing cardiac output and inhibiting renin release. It is used to treat hypertension and is studied in migraine.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Inderal, Inderal Xl, Innopran Xl
Drug type
Small molecule
Targets
beta-adrenergic receptor
Mechanism
Antagonist of beta-adrenergic receptor
Pathways
sympathetic nerve outflow, renin release, cardiac output
Therapy area
Neurology
Developer
Wyeth Pharms
In trials of
ABBV
FDA status
Approved as Inderal, Inderal Xl, Innopran Xl (November 13, 1967), NDA016418 · FDA label
UNII
9Y8NXQ24VQ

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 27, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06972056 Phase 4 Migraine Recruiting ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Migraine

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.